Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)Business Wire • 09/27/21
Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/10/21
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing PipelineBusiness Wire • 09/09/21
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing TherapiesBusiness Wire • 09/09/21
Tiziana Life Sciences races at US open after exclusive licensing agreement with Precision BioSciencesProactive Investors • 09/02/21
Tiziana Life Sciences surges on exclusive licensing agreement with Precision BioSciencesProactive Investors • 09/02/21
Tiziana Life Sciences inks exclusive licensing deal with US group Precision BioSciences that takes it into CAR-T therapyProactive Investors • 09/02/21
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer TreatmentBusiness Wire • 09/02/21
Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021Business Wire • 08/25/21
Precision BioSciences (DTIL) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/12/21
Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire • 08/12/21
Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/05/21
Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021Business Wire • 08/05/21
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin LymphomaBusiness Wire • 07/01/21
Precision BioSciences (DTIL) Surges 6.6%: Is This an Indication of Further Gains?Zacks Investment Research • 06/29/21